Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walker leaves CFSAN

This article was originally published in The Tan Sheet

Executive Summary

Susan Walker, MD, will depart CFSAN to head the Division of Dermatology & Dental Products in the Center for Drug Evaluation & Research's Office of New Drugs, FDA announces May 12. Walker joined the Center for Food Safety & Applied Nutrition in September 2003, where she served as director of the Division of Dietary Supplement Programs in the Office of Nutritional Products, Labeling, & Dietary Supplements. Among her responsibilities at CFSAN was the management of responses to structure/function claims and new dietary ingredient notifications. In May 2005, Walker received an HHS Secretary's Award for Distinguished Service for "outstanding performance" in development of the final rule prohibiting the sale of supplements containing ephedrine alkaloids, the agency notes...

You may also be interested in...



CFSAN Addresses AER Duplication, NDI Definition In Developing Guidances

FDA is working on a method to avoid duplication when tracking adverse event reports, according to the director of CFSAN's Division of Dietary Supplement Programs

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS099378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel